Our current data expand on these observations and demonstrate that both exogenous and tumour-derived Sema3A inhibited osteosarcoma-induced osteoclast formation and reduced osteosarcoma- and RANKL-induced osteoclast formation in vitro, indicative of a direct action on osteoclasts and their precursors. This evidence concerns the gene TNFSF11 and neoplasm.